Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1998-06-16
2000-04-11
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514561, 514562, A61K 3170, A61K 31195
Patent
active
060488433
DESCRIPTION:
BRIEF SUMMARY
Subject of the patent a medically beneficial preparation for external use containing amino acids.
The preparation according to the patent description is advantageously applicable for augmentation of the antiviral and anti-inflammatory effects of interferons and thimidine-analogous antiherpetic drugs, for amelioration of psoriatic symptoms and further, it is an effective drug against Herpes virus infections.
BACKGROUND OF THE INVENTION
Interferons are natural proteins with complex biological activity. Most important of their effects are antiviral, cell proliferation inhibitory and immune response enhancing properties. therapeutic use in tumour bearing patients.
Such applications are described in the following publications: J. biol. Regul. Homeostatic Agents, 1 pp 93-99 and 177-182, 1987; Intern. J. Cancer, 1987(Suppl.1.), pp 9-13, 1987; J. Interferon Res., Spec. Issue, 1992 April, pp 109-118.
Interferons are also effective in viral infections as it can be seen in the following publications: Lancet, i, p. 128, 1976; Transplantation Proc., 21, pp 2429-2430, 1989; Interferons in the Treatment of Chronic Virus Infections of the Liver, Pennine Press, Macclesfield, 1990.
They have also been proved beneficial in certrain inflammatory diseases: Neurology, 43, pp 655-661, 1993; J. Interferon and Cytokine Res., 15, pp 39-45, 1995.
The high doses applied for reaching a single therapeutic goal, however, may often provoke numerous unnecessary side effects due to the complex actions of these proteins (J. Rheumatol., 20, pp 83-85, 1992; J. Pediatr., 120(3), pp 429-431, 1992; Clin. Exp. Immunol., 90(3), pp 363-367, 1992).
These side effects are quite often dose-limiting factors in the therapeutic use of interferons.
Typically, interferons are applied in combination for therapeutic purposes in order to decrease the severity of side effects. Several different approximations are applicable for combination therapies such as: decrease in the necessary (loses by complementation with drugs of similar mechanism of action (J. Natl. Cancer Inst., 83 pp 1408-1410, 1991); combination with drugs of antagonistic mechanism of action in order to selectively reduce harmful side effects (J. Biol. Resp. Modifiers, 5, pp 447-480, 1986); selective augmentation of the required therapeutic effect by addition of potentiating components or by application of appropriate physical conditions, e.g. hyperthermia (Proc. Soc. Exp. Biol. Med., 169, pp 413, 1982).
It is known from the publications that effective therapeutic application of thimidine-analogous drugs (deoxyuridine derivatives substituted at the 5 position) with antiherpetic action is seriously limited by that fact that a fast viral resistance develops in response to therapeutic concentrations of these drugs. Viral strains resistant to one given drug show crossresistance to other ones with similar chemical structure. Dose reduction of these drugs--if it could be achieved--would reduce the selection pressure on the viruses, thereby reducing, the frequency of the development of resistant mutants and consequently enhancing the therapeutic value of the known antiherpetic agents.
SUMMARY OF THE INVENTION
The purpose of this invention is to enhance selectively the antiviral effects of interferons and antiherpetic thimidine-analogues in order to be able to decrease the effective therapeutic doses.
It was also intended to develop a drug combination beneficial in herpetic infections and effective in reducing or eliminating skin symptoms of psoriasis.
One aim of the inventions is to produce an ointment and liquid for external use which contains low dose (and, thus, free of side effects) antiviral drugs (interfernon, 5-ethyl-2'-deoxyuridine=EDU, 5-iodo-2'-deoxyuridine=IDU,) combined with components (amino acids) selectively potentiating the antiviral activity and the interferon-mediated inhibition of inflammation.
Our invention is based on the recognition that some amino acids are able to potentiate the antiherpetic effect of the thimidine analogue drugs by a factor of several grades (10.sup.2 -10.
REFERENCES:
patent: 4710376 (1987-12-01), Evans et al.
patent: 4880785 (1989-11-01), Szabolcs nee Borbas et al.
patent: 5236704 (1993-08-01), Fujioka et al.
Jones et al., Lancet, vol. 2, No. 7977, p. 128 (Jul. 17, 1976).
Mancini et al., Transplantation Proceedings, vol. 21, No. 1, pt.2, p. 2429-2430 (Feb. 1989).
Toth et al., "Effect of Amino Acids on the Expression of Antiviral Activity of Different Types of Human Interferon", Acta Microbiologica Hungarica, vol. 32, No. 4, p. 363-368 (1985).
Toth et al., "Effect of Amino Acids on the Expression of Antiviral Activity of Different Types of Human Interferon", Acta Microbiologica Hungarica, vol. 32, No. 4, p. 369-372 (1985).
LandOfFree
Topical composition containing amino acid in combination with ei does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical composition containing amino acid in combination with ei, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical composition containing amino acid in combination with ei will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1176658